23-10-2024

Adjuvant therapy options for high-risk breast cancer

Tjoung-Won Park-Simon is a Professor and Head of the Division of Gynecologic Oncology and Breast Oncology (tenure), Deputy Chairman of the Department of Obstetrics and Gynecology at the Medical School of Hannover, as well as Investigator of numerous clinical trials (phase1-3).

Adjuvant treatment of early breast cancer has become complex. Endocrine treatment remains the backbone of adjuvant therapy for hormone receptor –positive early stage breast cancer. In high-risk breast cancer the addition of CDK4/6 inhibitors to adjuvant endocrine therapy improves survival and is now approved. Parp-Inhibitors significantly improve survival in patients with high-risk breast cancer and gBRCA mutation and are also approved in the adjuvant setting. For patients with high-risk TNBC immunecheckpoint inhibitors are approved and available. Parp-inhibitors are also available in high-risk TNBC. A number of studies are ongoing exploring de-escalation strategies. I will present some cases to illustrate the current advances we made but also to show limitations in clinical practice.